Ultra-processed food addiction, an overlooked health crisis among older adults
A surprising 12% of older Americans are addicted to ultra-processed foods—a rate that surpasses alcohol or tobacco addiction in this age group. For.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
A surprising 12% of older Americans are addicted to ultra-processed foods—a rate that surpasses alcohol or tobacco addiction in this age group. For.
A study from the Salk Institute has found HIV’s ability to hijack human cells, uncovering a shape-shifting viral protein that could transform treatments for the.
The European Union approved AstraZeneca Plc and Amgen Inc.’s add-on therapy to treat adults with a chronic inflammatory condition of the nasal passages.
China’s Innovent Biologics and Takeda Pharmaceutical Co. announced a $11.4 billion licensing deal, which will enable the former to speed up the development.
Hologic Inc., which specialises in women’s health diagnostics, is set to be acquired in a deal worth $18.3 billion backed by asset managers.
The Food and Drug Administration has approved Glaukos Corporation’s drug to treat keratoconus, a rare, sight-threatening eye disease that is currently far too.
Merck and Co. will invest up to $70 billion to expand its domestic manufacturing in the US after President Donald Trump urged pharmaceutical.
Novo Nordisk will acquire US-based Akero Therapeutics, Inc. for $5.2 billion to pocket an experimental drug in end-stage trials to treat liver disease,.
Zenas BioPharma, Inc. and China’s InnoCare Pharma Limited have inked a $2 billion licensing deal that grants the US-based Zenas global rights to.
University of Cambridge scientists have developed a first-time imaging technique that helps visualise and quantify the early triggers of Parkinson’s — the world’s.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com